Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Anterix director Leslie B. Daniels sells 2,500 common shares worth $209,575

Anterix director Leslie B. Daniels sells 2,500 common shares worth $209,575

ReutersReuters2026/09/11 20:09
  • Anterix director Leslie B. Daniels sold 2,500 common shares on Sept. 10, 2026 at USD 83.83.
  • Direct holdings fell to 43,477 shares.
  • Indirect holdings of 7,000 shares remained, held via an IRA and 401K.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Anterix Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001052559-26-000006), on September 11, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Saving in the US, paying globally? Industry research warns: Trump’s push to lower drug prices could instead incentivize pharmaceutical companies to raise prices overseas

A study published in The Lancet indicates that Trump's efforts to lower drug prices in the United States may force pharmaceutical companies to raise prices internationally or exit certain markets, potentially leading to a significant reduction in the approximately $11.6 billion saved annually by Medicare.

智通财经2026/09/14 00:46
Saving in the US, paying globally? Industry research warns: Trump’s push to lower drug prices could instead incentivize pharmaceutical companies to raise prices overseas